-
Cystic Fibrosis Foundation grants $5 Mn to Armata Pharmaceuticals for CF therapy
- March 26, 2020
- Posted by: PharmaScroll
- Category:
No Comments -
KALYDECO in Cystic Fibrosis receives positive CHMP opinion by EMA
- October 21, 2018
- Posted by: PharmaScroll
- Category:
-
Positive results from new triple combinations in Cystic Fibrosis, displayed by Vertex
- October 21, 2018
- Posted by: PharmaScroll
- Category:
-
Synspira’s drug receives FDA Orphan Designation for Cystic Fibrosis treatment
- October 16, 2018
- Posted by: PharmaScroll
- Category:
-
FDA Approves ORKAMBI in Cystic Fibrosis for Children Ages 2-5 Years
- August 13, 2018
- Posted by: PharmaScroll
- Category:
-
Boehringer Ingelheim to Develop novel Gene Therapy for Cystic Fibrosis
- August 7, 2018
- Posted by: PharmaScroll
- Category:
-
Kalydeco (ivacaftor) Data Demonstrates Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of Cystic Fibrosis
- June 7, 2018
- Posted by: PharmaScroll
- Category:
-
Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis
- April 30, 2018
- Posted by: PharmaScroll
- Category: